Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine

被引：38

作者：

Lennerstrand, J

Stammers, DK

Larder, BA

机构：

[1] Virco UK Ltd, Cambridge CB4 0GA, England

[2] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 07期

关键词：

D O I：

10.1128/AAC.45.7.2144-2146.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We have found a close correlation between viral stavudine (d4T) resistance and resistance to d4T-triphosphate at the human immunodeficiency virus type 1 reverse transcriptase (RT) level, RT from site-directed mutants with 69S-XX codon insertions and/or conventional zidovudine resistance mutations seems to be involved in an ATP-dependent resistance mechanism analogous to pyrophosphorolysis, whereas the mechanism for RT with the Q151M or V75T mutation appears to be independent of added ATP for reducing binding to d4T-triphosphate.

引用

收藏

页码：2144 / 2146

页数：3

相关论文

共 26 条

[1] Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT):: Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase [J].

Arion, D ;

Kaushik, N ;

McCormick, S ;

Borkow, G ;

Parniak, MA .

BIOCHEMISTRY, 1998, 37 (45) :15908-15917

[2]

Ekstrand DHL, 1996, BIOTECHNOL APPL BIOC, V23, P95

[3] INFECTION OF HTLV-III/LAV IN HTLV-I-CARRYING CELLS MT-2 AND MT-4 AND APPLICATION IN A PLAQUE-ASSAY [J].

HARADA, S ;

KOYANAGI, Y ;

YAMAMOTO, N .

SCIENCE, 1985, 229 (4713) :563-566

[4] Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility [J].

Harrigan, PR ;

Kinghorn, I ;

Bloor, S ;

Kemp, SD ;

Najera, I ;

Kohli, A ;

Larder, BA .

JOURNAL OF VIROLOGY, 1996, 70 (09) :5930-5934

[5] Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. -: J Antimicrob Chemother 1998; 42:269-270 [J].

Vahaboglu, H ;

Saribas, S ;

Akbal, H ;

Ozturk, R ;

Yucel, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :269-270

[6] Stavudine - An update of its use in the treatment of HIV infection [J].

Hurst, M ;

Noble, S .

DRUGS, 1999, 58 (05) :919-949

[7] 5TH MUTATION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CONTRIBUTES TO THE DEVELOPMENT OF HIGH-LEVEL RESISTANCE TO ZIDOVUDINE [J].

KELLAM, P ;

BOUCHER, CAB ;

LARDER, BA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1934-1938

[8] RECOMBINANT VIRUS ASSAY - A RAPID, PHENOTYPIC ASSAY FOR ASSESSMENT OF DRUG SUSCEPTIBILITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].

KELLAM, P ;

LARDER, BA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) :23-30

[9] Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC [J].

Krebs, R ;

Immendorfer, U ;

Thrall, SH ;

Wohrl, BM ;

Goody, RS .

BIOCHEMISTRY, 1997, 36 (33) :10292-10300

[10] NOVEL MUTATION (V75T) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CONFERS RESISTANCE TO 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE IN CELL-CULTURE [J].

LACEY, SF ;

LARDER, BA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) :1428-1432